During the final quarter of 2025, the BlackRock Health Sciences Term Trust achieved commendable financial results. Its market price saw an increase of 6.7%, while its net asset value (NAV) grew by 8.6%. This performance outpaced the STOXX Global Breakthrough Healthcare Index, which recorded a 9.9% return over the same period. A strategic shift in the Trust's investment focus was observed, with an enhanced allocation to the pharmaceutical sector and a reduction in its exposure to healthcare providers and services.

The investment landscape for the BlackRock Health Sciences Term Trust in Q4 2025 was characterized by a concerted effort to capitalize on growth opportunities within the healthcare industry. The Trust's decision to bolster its position in pharmaceuticals reflects a belief in the sector's potential for innovation and structural expansion. Conversely, the reduction in healthcare providers and services suggests a more cautious outlook or a reallocation of resources towards areas deemed to offer higher growth prospects.

A significant aspect of the Trust's strategy involved its engagement with private companies. Approximately 13.4% of the portfolio's NAV, amounting to $143 million, was invested across 21 private entities. This allocation highlights the Trust's inclination towards early-stage healthcare innovators, which, while potentially carrying higher liquidity and valuation risks, are also expected to deliver substantial long-term returns. This approach underscores a proactive investment philosophy aimed at diversifying holdings and capturing emerging value.

The Trust's distribution strategy relies primarily on capital gains and the return of capital, rather than solely on income generation. In 2025, a significant 75% of distributions were attributed to the return of capital, indicating a model that prioritizes asset sales to fund investor payouts. This strategy shapes the risk-reward profile of the Trust, offering investors exposure to dynamic healthcare innovation but also implying a dependence on successful asset monetization for distributions.

Looking ahead, the BlackRock Health Sciences Term Trust is positioning its portfolio to navigate the evolving healthcare market. By continuously adjusting its sector exposures and maintaining a notable presence in private investments, the Trust aims to sustain its growth trajectory. These strategic adjustments are crucial for adapting to market dynamics and optimizing returns, balancing potential risks with the opportunities presented by innovative healthcare advancements.

The views expressed in this commentary reflect BlackRock's opinions as of December 31, 2025, and are subject to change based on shifts in market, economic, or other conditions. These insights are not a guarantee of future outcomes.